Clinical trials: Second-Line
Urothelial Carcinoma
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
This study represents an innovative opportunity in the treatment of metastatic urothelial carcinoma
- Trial name
- AVESEC (NCT07460245)
- Testing
- Avelumab 800 mg flat-dose IV
- Where
- 19 sites in Italy
- Volunteers
- 144 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.
- Trial name
- NCT02999295
- Testing
- Ramucirumab, Nivolumab
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- National Cancer Center, Japan
Acute Severe Ulcerative Colitis
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
This clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can…
- Trial name
- NCT07550673
- Testing
- upadacitinib, Infliximab
- Where
- 4 sites in China
- Volunteers
- 226 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Lymphoma
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
- Trial name
- NCT07779018
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liping Dou
Stomach Cancer, Gastric Cancer
Docetaxel and Irinotecan in Gastric Cancer
To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.
- Conditions
- Stomach Cancer, Gastric Cancer, Chemotherapy Effect
- Trial name
- NCT04770623
- Testing
- Docetaxel, Irinotecan
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Menoufia University
Stomach Neoplasm
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free survival rate (primary end-point) and response rate, toxicity, and overall survival (secondary end-points) in patients with metastatic…
- Trial name
- NCT00729482
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
PDAC - Pancreatic Ductal Adenocarcinoma
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
The main objective of PANORAMIX phase II trial is to optimize first-lie (L1) NALIRIFOX treatment for pancreatic cancer through the implementation of 5-fluorouracil (5-FU) maintenance therapy.
- Trial name
- PANORAMIX (NCT07028424)
- Testing
- Nal-IRI, Ciprofloxacin, Paclitaxel
- Where
- 12 sites in France
- Volunteers
- 206 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
HCC - Hepatocellular Carcinoma
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
The goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line…
- Trial name
- NCT07187284
- Testing
- EDN combined with TACE/HAIC and Immuno-Targeted Therapy, TACE/HAIC plus Immuno-Targeted Therapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongda Hospital
Urothelial Carcinoma, Kidney Cancer
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
This is a phase 2 study of the drug denosumab for the management bone metastases from urothelial cancer. The purpose of this study is to find out how effective denosumab is in the management of bone metastases from urothelial…
- Conditions
- Urothelial Carcinoma, Kidney Cancer, Ureter Cancer, Bladder Cancer
- Trial name
- NCT03520231
- Testing
- Denosumab, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
A growing body of literature supports the role of angiogenesis in the development and spread of a variety of human cancers including prostate cancer.
- Trial name
- NCT00945477
- Testing
- Pazopanib (GW786034)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Illinois CancerCare, P.C.
Metastatic Colorectal Cancer
Sequential Treatment Strategy for Metastatic Colorectal Cancer
Study Design: This is a pragmatic study on the management strategy for patients with metastatic colorectal cancer (CRC) who are candidates for CT, independently of any previous adjuvant therapy received.
- Trial name
- ITACa (NCT01878422)
- Testing
- Arm A: FOLFIRI or FOLFOX + Bevacizumab, Arm B: FOLFIRI or FOLFOX, Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
- Where
- 23 sites in Italy
- Volunteers
- 376 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Hodgkin Lymphoma
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory…
- Trial name
- ANIMATE (NCT03337919)
- Testing
- Nivolumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- University College, London
Pancreatic Ductal Adenocarcinoma (mPDAC)
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose…
- Trial name
- SWITCH (NCT06790602)
- Testing
- Cemiplimab Plus Gemcitabine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Diego
Overactive Bladder (OAB), Lower Urinary Tract Dysfunction
Parasacral TENS Project
The purpose of the project is to compare the efficacy of parasacral transcutaneous electric nerve stimulation (TENS) versus standard second-line therapy (oral anticholinergics) for pediatric patients with overactive bladder (OAB)…
- Trial name
- NCT07892417
- Testing
- Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Gastroenteropancreatic Neuroendocrine Tumor
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
- Trial name
- NCT01994213
- Testing
- Famitinib
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
SCLC
Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
Investigators propose to study the single agent activity of pazopanib in a Phase II trial of patients with relapsed or refractory small cell lung cancer.
- Trial name
- NCT01713296
- Testing
- Pazopanib
- Where
- 8 sites in Greece
- Volunteers
- 58 people
- Sponsor
- Hellenic Oncology Research Group
Small Cell Lung Cancer
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Immunotherapy combined with anti-angiogenic therapy can achieve better results in patients with second-line and above small cell lung cancer
- Trial name
- NCT04192682
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changzhou Cancer Hospital of Soochow University
Small Cell Lung Carcinoma
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC…
- Trial name
- NCT04938817
- Testing
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830
- Where
- 48 sites in United States, Australia and 10 more
- Volunteers
- 110 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus standard second-line chemotherapy.
- Trial name
- NCT04385550
- Testing
- Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection
- Where
- 45 sites in China
- Volunteers
- 528 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer.
- Conditions
- Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis)
- Trial name
- IKF-ReWoLuTe (NCT07510724)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 240 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.